Prostanoid Receptors Involved in Regulation of the Beating Rate of Neonatal Rat Cardiomyocytes

Hakima Mechiche¹², Stanislas Grassin-Delyle², Arnaud Robinet¹, Pierre Nazeyrollas¹, Philippe Devillier¹²

¹Laboratory of Cardiovascular Pharmacology, Université Champagne Ardennes, Reims, France, ²UPRES EA 220, Université Versailles Saint-Quentin en Yvelines, Hôpital Foch, Suresnes, France

Abstract

Although prostanoids are known to be involved in regulation of the spontaneous beating rate of cultured neonatal rat cardiomyocytes, the various subtypes of prostanoid receptors have not been investigated in detail. In our experiments, prostaglandin (PG)F₂α and prostanoid FP receptor agonists (fluprostanol, latanoprost and cloprostenol) produced a decrease in the beating rate. Two prostanoid IP receptor agonists (iloprost and beraprost) induced first a marked drop in the beating rate and then definitive abrogation of beating. In contrast, the prostanoid DP receptor agonists (PGD₂ and BW245C) and TP receptor agonists (U-46619) produced increases in the beating rate. Sulprostone (a prostanoid EP1 receptor agonist) induced marked increases in the beating rate, which were suppressed by SC-19220 (a selective prostanoid EP1 antagonist). Butaprost (a selective prostanoid EP2 receptor agonist), misoprostol (a prostanoid EP2 and EP3 receptor agonist), 11-deoxy-PGE₁ (a prostanoid EP2, EP3 and EP4 receptor agonist) did not alter the beating rate. Our results strongly suggest that prostanoid EP1 receptors are involved in positive regulation of the beating rate. Prostanoid EP2 receptor expression was confirmed by western blotting with a selective antibody. Hence, neonatal rat cardiomyocytes express both prostanoid IP and FP receptors (which negatively regulate the spontaneous beating rate) and prostanoid TP, DP1 and EP1 receptors (which positively regulate the spontaneous beating rate).

Introduction

Prostanoids exert a wide variety of effects on cardiac tissue [1]. The prostanoid receptors include the DP, EP, FP, IP and TP receptors [2,3], which preferentially bind prostaglandin D (PGD), PGE, PGF, PGI and thromboxane A (TXA), respectively, and belong to the G-protein-coupled receptor superfamily [4]. The prostanoid EP receptor type has EP₁, EP₂, EP₃ and EP₄ subtypes and the DP receptor type has DP₁ and DP₂ subtypes [4]. Although endogenous prostanoids tend to bind most strongly to a given prostanoid receptor class, there is a marked degree of cross-reactivity between these ligands and the entire receptor family [2,5]. This taxonomy has only been described fairly recently, following the availability of selective agonists and, to lesser degree, a few selective antagonists [6]. Molecular biology techniques have confirmed this pharmacological classification via the cloning of cDNAs for representatives of each type of prostanoid receptor in a number of species (including the human, the rat and the mouse [2,4,7,8].

In the heart, prostanoid synthesis is enhanced after (i) ischemia produced in situ by coronary artery ligation or (ii) exposure to inflammatory cytokines [1,9,10]. The cardiac production of prostanoids appears to be involved in ischemic preconditioning’s protective effect against reperfusion-induced tachyarrhythmia in the isolated rat heart [11,12] and mediates inflammation-associated tachycardia in mice [10]. Furthermore, the fact that endogenous prostanoids can alter the beating rate of neonatal rat cardiomyocytes [13] provides additional insight into the relationship between these compounds and cardiac arrhythmia. Neonatal rat cardiomyocytes - which beat spontaneously, synchronously and rhythmically - provide a useful preparation for assessing the direct chronotropic and arrhythmogenic effects of pharmacological agents and avoid the possible confounding effects of neurogenic or circulating humoral factors [13,14]. However, the receptors involved in the prostanoids’ chronotropic effects in this preparation have not been systematically investigated by applying selective, synthetic prostanoid receptor agonists or antagonists.

The main objective of the present study was thus to characterize the prostanoid receptor types and subtypes involved in regulation of the spontaneous beating rate of neonatal rat cardiomyocytes. To that end, we mainly applied selected potent, prostanoid type-selective, synthetic prostanoid receptor agonists or antagonists.

Materials and Methods

Cell culture

This study was approved by the Faculty of Pharmacy and Medicine in Reims. Spontaneously beating neonatal rat cardiomyocyte cultures were obtained from 2- to 4-day-old Sprague-Dawley rats. The animal facilities and the staff involved in the
animal experiments were accredited by the Veterinary Service of the French Ministry of Agriculture. The rats were deeply anesthetized with 30 mg/kg of sodium pentobarbital injected intraperitoneally. Briefly, heart tissue was washed with Eagle's minimum essential medium (MEM) (Sigma, St-Louis, MO, USA) containing 10% foetal calf serum (FCS) (DAP, Vogelgrun, France), 2 mM glutamine (Institut J. Boy, Reims, France), penicillin 1,000 U/ml (Specia, Paris, France) and streptomycin 0.1 mg/ml (Diamant, Puteaux, France) and buffered at pH 7.4 with sodium bicarbonate. Ventricular heart tissue was cut into small pieces, further washed with MEM and enzymatically digested for 15 minutes with 25 mM of phosphate-buffered saline with 40 U/ml collagenase (Sigma, St-Louis, MO, USA) at 37°C with constant stirring. The supernatant from the initial incubation was discarded, 25 ml of fresh enzyme solution were added and the incubation procedure was repeated six times. Subsequent supernatants were collected and centrifuged at 250 g for 5 min. The resulting cell pellets were resuspended in MEM at 37°C, pooled (3×10^7 cells/ml) and seeded in 60 mm culture dishes (Corning, New York, USA) at a density of 1.8×10^6 cells/dish. The cell cultures were incubated at 37°C in 95% air/5% CO2 for three days, with the medium changed daily. Most of the cultured cells (>90%) began to contract spontaneously within 24–48 h of plating. Confluent, spontaneously beating cells from day 3 of culture were used for all experiments, since homogenization of the beating rates was observed at day 3. Prior to experimental treatments, cell cultures were washed twice and incubated for 1 h with MEM containing 2% foetal calf serum and 1 μM indomethacin. This pretreatment was performed in order to avoid interference by endogenous prostanoids produced by the cardiomyocytes [9]. Indomethacin did not alter the beating rate, as previously shown by Li et al. [13]. All drug solutions were prepared daily.

Measurement of the beating rate

The culture dish was placed on the heating stage of an inverted phase contrast microscope (model CK2 TR from Olympus Optical, Tokyo, Japan). The cells were magnified using a 20× objective and the image was monitored with a charge-coupled device camera (model 4712–7000 from Cohu, San Diego, CA, USA) attached to the microscope observation tube using an 6.7 coupler. The video output was connected to a television monitor (model VM-1221 from Hitachi Denshi, Tokyo, Japan).

The beating rate was determined simultaneously by two researchers, who measured the time required for 20 beats. Each researcher performed two independent measurements with a 30-second interval. At the end of each series of experiments, the time required for 20 beats was converted into a frequency per minute and the mean of the four determinations was calculated. The beating rate was measured every two minutes during the 10 minutes immediately preceding addition of the test compound.

The vials containing the test compound solutions were coded for random, blind application to the cardiomyocyte cultures. Two different methods were used. The first consisted of simply adding 100 μl of solution to the culture dish, in order to expose the cells to a concentration of 1 μM. The beating rate was then measured during the first minute and then every other minute over a 21-minute period. This screening method was used to identify compounds that caused significant, reproducible changes in the beating rate and to study the time course of these changes. This screening method was also used to study the responses to different concentrations of PGF2α and sulprostone. The second method consisted in exposing cell cultures to cumulative increases (from 1 nM to 1 μM to 1 log-increments) in the concentration of a selected compound. The concentration was increased every 7 minutes, since an optimal response was always observed within 5 minutes of addition. The beating rate was measured for 1 minute after each concentration change and then every other minute during each 5-minute interval. For experiments with the prostanoid EP1 receptor antagonist SC-19220, the compound was added to the culture dishes 13 minutes before addition of sulprostone. In all experiments, concentrations are quoted as the final molarity in the culture dishes. No more than two experiments were conducted with one agonist on dishes from the same culture preparation. For each series of experiments, control experiments were performed by applying the corresponding volumes of the compound's vehicle. A cell viability assay (trypan blue dye exclusion) was performed on at least two rat cardiomyocyte preparations at the end of experiments with vehicles or the compounds. Cell viability exceeded 90% in all cases. The stability of the beating frequency was checked on control dishes at least twice (e.g. at the beginning and end of each series). The beating frequency (129±4 beats/min, n = 188) was found to be stable over each series of experiments.

Western blot analysis of prostanoid EP1 receptor expression

The membranes of the cultured rat cardiomyocytes were extracted with ice-cold lysis buffer (75 mM NaCl, 20 mM Hepes, 2.5 mM MgCl2, 0.1 mM EDTA, 0.1% Triton X-100, 10 μg/ml aprotinin, 20 mM glycerophosphate, 0.5 mM dithiothreitol, 0.1 mM sodium orthovanadate, 200 μg/ml phenylmethylsulphonyl fluoride and 1 mM sodium fluoride, pH 7.7). Samples were adjusted to the same protein concentration (determined using a BCA assay, Interchim, Montluçon, France). Aliquots of supernatant containing 20 μg of protein were boiled in sample loading buffer for 5 minutes and then loaded onto a 10% SDS-polyacrylamide gel and electrophoretically transferred to Immobilon-P membranes (Millipore, Saint Quentin en Yvelines, France). Non-specific binding sites on the membranes were blocked with 5% fat-free milk in 20 mM Tris-buffered saline (150 mM NaCl) plus 0.1% Tween-20 at pH 7.4 (TBST). The membranes were incubated in 5% fat-free milk in TBST containing a rabbit polyclonal anti-prostanoid EP1 receptor antibody (Cayman Chemicals, distributed by SPI-Bio, Massy, France) overnight at 4°C. The latter antibody had been raised against a synthetic peptide from the human prostanoid EP1 receptor (C-terminal amino acids 380–402; GLTPSA-WEASSLRSSRHSGLSHF) conjugated to keyhole limpet haemocyanin. The antibody cross-reacts with rat prostanoid EP1 receptor (84% amino acid identity with its human counterpart) but does not bind to prostanoid EP2, EP3 or EP4 receptors. The membranes were then incubated with horseradish peroxidase-conjugated anti-rabbit IgG antibody in TBST overnight at 4°C. The antibody was visualized by horseradish peroxidase-conjugated anti-rabbit IgG antibody in TBST for 1 h at room temperature. Lastly, immunoreactive bands were visualized with a chemiluminesence reagent (Amersham, France).

Drugs

Prostanoids and synthetic analogues were all obtained from Cayman Chemicals (SPI-Bio): PGD2: [5Z,9a,11α,13E,15S]-9,13-dihydroxy-11-oxoprosta-5,13-dienoic acid; PGE2: methyl [5Z,9a,13E,15S]-11,13-dihydroxy-9-oxo-prosta-5,13-dien-1-0ic acid; PGF2α: [5Z,9a,11α,13E,15S]-9,11,15-trihydroxyprosta-5,13-dienoic acid; U-46619: 9,11-dideoxy-9,12α-methanoepoxy prostaglandin F2α, 8-iso PGF2α: prosta-5,13-dien-1-0ic acid, 9,11,15-trihydroxy-, (3,15)[8Z,9a,11α,13E,15S]; BW245C: 4-imidazolidineheptanoic acid, 3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxo-, (R*,S*); sulprostone: 5-heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butanyl)-3-

PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e45273
oxocyclopentyl]-N-(methylsulfonyl)-[1R-1α(Z);2β(1E,3R*,3α)]; misoprostol: 9-oxo-11α, 16-dihydroxy-16-methyl-prost-13E-en-1-olic acid, methyl ester; 11-deoxy PGE1: prost-13-en-1-olic acid, 15-hydroxy-9-oxo-, [13E, 15S]; fluprosteno: 5-heptenoic acid, 7-[3,5-dihydroxy-2-(3-hydroxy-4-{[3-(trifluoromethyl)phenoxyl]-1-butenyl}[cyclopentyl]-, [1α(Z);2β(1E,3R*,3α)]; latanoprost: 9α, 11α, 13S-trihydroxy-17-phenyl-18,19,20-tetranor-prost-5Z, 13E-dien-1-olic acid; butaprost: 9-oxo-11α,16R-dihydroxy-17-cyclobutyl-prost-13E-en-1-olic acid, methyl ester; iloprost: 5-[E]-[1S,5S,6R,7R]-7-hydroxy-6-[E]-(3S,4RS)-3-hydroxy-4-methyl-1-octenyl]-bicyclo[3.3.0]octan-3-ylidene]pentanoic acid; beraprost: 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-buta-noic acid; SC-19220: 8-chloro-dibenz[b,f][1,4]oxazepine-10(11H)-carboxy-(2-acetyl)hydrazide. PGD2, PGE2, PGF2, 8-isoPGF2α, BW 245 C, 11-deoxy PGE1 cloprostenol, beraprost and SC-19220 were supplied as crystalline powders, reconstituted with dimethyl sulfoxide (DMSO), stored at -20°C and further diluted in culture medium for use in experiments. U-46619, sulprostone, misoprostol, latanoprost, butaprost and iloprost were supplied as solutions in methylacetate. The methylacetate was evaporated and replaced by DMSO for storage at -20°C. Immediately prior to performance of the experiments, compound solutions in DMSO were diluted in culture medium. Fluprostenol was supplied as a solution in ethanol and then diluted in culture medium. The final concentrations of DMSO or ethanol never exceeded 0.2% and had no effect on the cardiomyocyte beating rates.

Data processing and statistical analysis

All values correspond to the mean±the standard error of the mean (SEM). For each culture, differences in the beating rate were judged by comparing the mean frequency prior to addition of the compound and the peak frequency observed during the 21-minute period following addition of the compound (for the first method) or the 7-minute period following each concentration change (for the second method).

### Table 1. Effects of endogenous prostanoids and selective agonists on the beating rate of neonatal rat cardiomyocytes.

| Prostanoid agonists (1 μM) | Receptor selectivity a | n | % change vs baseline | Brady- arrhythmia (n) | Tachy- arrhythmia (n) |
|---------------------------|------------------------|---|----------------------|----------------------|----------------------|
| **FP agonists** PGE2a      |                        |   |                      |                      |                      |
| Fluprosteno               | FP, EP3                | 7 | -23±9 *              | 1                    | -                    |
| Latanoprost               | FP                     | 7 | -18±5 *              | 1                    | -                    |
| Cloprostenol              | FP                     | 7 | -34±5 *              | 2                    | -                    |
| **IP agonists**           |                        |   |                      |                      |                      |
| Iloprost                  | IP, EP1, EP3           | 7 | -54±14 *             | 4                    | -                    |
| Beraprost                 | IP                     | 7 | -35±13 *             | 2                    | -                    |
| **DP agonists**           |                        |   |                      |                      |                      |
| PGD2                     | DP, FP, EP3            | 5 | 26±11 *              | -                    | 1                    |
| BW245 C                  | DP1                    | 6 | 15±4 *               | -                    | -                    |
| **TP agonist**            |                        |   |                      |                      |                      |
| U-46619                  | TP                     | 5 | 25±15 *              | -                    | 2                    |
| **EP agonists**           |                        |   |                      |                      |                      |
| PGE2                     | EP, FP                 | 12| 3±5                  | -                    | -                    |
| Sulprostone               | EP, EP3                | 9 | 35±6 *               | -                    | 1                    |
| Butaprost                 | EP2                    | 7 | 4±4                  | -                    | -                    |
| Misoprostol               | EP3>EP1, EP3           | 6 | 8±5                  | -                    | -                    |
| 11-deoxy-PGE1             | EP3>EP2, EP2           | 5 | 7±2                  | -                    | -                    |

* p<0.05; n is the number of independent preparations used; receptor selectivity as previously reported [4,7,8]. “bradyarrhythmia” indicated a decrease of more than 50%; “tachyarrhythmia” indicated an increase of more than 50% with chaotic, asynchronous, activity of the myocytes [13]; n is the number of preparations on which brady- or tachy-arrhythmia was observed.

doi:10.1371/journal.pone.0045273.t001

Figure 1. Effect of prostanoid IP and FP agonists on the cardiomyocyte beating rate. Cumulative concentration-response curves are shown for iloprost (●, n = 5), beraprost (■, n = 6), latanoprost (▲, n = 5) and cloprostenol (●, n = 5). Values are expressed as percent decrease (means±SEM from 5 or 6 experiments performed in duplicate).

doi:10.1371/journal.pone.0045273.g001
second method). Variations in the beating rate were evaluated in an analysis of variance (ANOVA) for repeated measures, followed by a Bonferroni-Dunn test. The threshold for statistical significance was set to p<0.05. Effects on the myocytes' beating rate were expressed as a percentage of the basal rate; “bradyarrhythmia” indicated a decrease of more than 50% and “tachyarrhythmia” for an increase of more than 30% with chaotic, asynchronous, activity of the myocytes (as previously described by Li et al. [13].

The concentration-effect curves were analysed using non-linear regression implemented with GraphPad Prism software (version 5.01 from GraphPad Software Inc., San Diego, CA, USA). Sigmoidal curves were plotted to analyse the effects of agonists. The potency (pD2) of prostanoid receptor agonists was defined as the negative log10 of the agonist concentration achieving 50% of the maximal response (EC50) calculated by GraphPad Prism.

Results

Effects of prostanoid FP and IP receptor agonists

At a concentration of 1 μM, PGF2α and the prostanoid FP receptor agonists fluprostenol, latanoprost and cloprostenol produced a significant decrease in the myocytes' beating frequency (Table 1). Cumulative addition (1 nM to 1 μM) of cloprostenol or latanoprost induced a concentration-dependent decrease in the beating rate; the pD2 values were 8.4±0.3 (n = 5) and 7.9±0.3 (n = 5), respectively (Fig. 1). A cumulative, concentration-dependent experiment was not performed with the two weakest agonists (i.e., PGF2α and fluprostenol).

At 1 μM, the prostanoid IP-receptor agonists iloprost and beraprost produced a marked reduction in the beating rate of the myocytes – indeed, in some experiments, the culture stopped beating and did not restart (Table 1). Prior to the beating arrest, the cardiomyocytes took on a stellate appearance and beat asynchronously. Cumulative addition (1 nM to 1 μM) of each of the compounds caused a concentration-dependent slowing of the rate; the pD2 values were 7.7±0.4 (n = 5) for iloprost and 7.7±0.7 (n = 6) for beraprost (Fig. 1).

Effects of prostanoid DP and TP receptor agonists

At 1 μM, PGD2, BW245C (a specific prostanoid DP1 receptor agonist) and U-46619 (a stable TxA2 analogue selective for prostanoid TP receptor) produced significant increases in the myocytes' beating rate (Table 1). The isoprostane 8-iso-PGF2α also acted as a specific prostanoid TP receptor agonist [15] at this concentration but was less potent than U-46619, since it increased the beating rate weakly and inconsistently (data not shown, n = 11). Tachyarrhythmia was observed with PGD2 and U-46619.

Effects of prostanoid EP receptor agonists

At 1 μM, neither PGE2 (a non-selective agonist of the four prostanoid EP receptor subtypes), butaprost (a selective prostanoid EP2 receptor agonist), misoprostol (a prostanoid EP2 and EP3 receptor agonist) nor 11-deoxy-PGE1 (a prostanoid EP2, EP3, and EP4 receptor agonist) altered the spontaneous beating rate (Table 1). Since 11-deoxy-PGE1 is more selective for the three prostanoid receptor subtypes at lower concentrations [7,8], we performed experiments (n = 4) at concentrations ranging from 1 nM to 1 μM. However, no significant effects were observed (data not shown).

In contrast, the prostanoid EP1 and EP3 receptor agonist sulprostone (0.1–1 μM) rapidly (after 30 seconds) produced significant increases in the beating rate, with tachyarrhythmia occurring at 1 μM in 1 of the 9 experiments (Table 1). In three experiments, the cells were exposed to 5 μM of sulprostone without a further increase in the beating rate (data not shown). These effects were sustained throughout the experiments. Cumulative addition of sulprostone (1 nM to 1 μM) induced concentration-dependent increases in the beating rate of similar magnitude to those in the previous series, with a pD2 value of 7.4±0.5 nM (Fig. 2). Furthermore, pre-incubation of the cardiomyocytes with SC-19220 (50 μM) suppressed the sulprostone-induced (1 μM) increase in the beating rate by 34±8% (Fig. 2).

Western blot analysis of prostanoid EP1 receptor expression

A Western blot analysis of prostanoid EP1 receptor expression at rat cardiomyocyte membranes (Fig. 3) clearly identified a 42-kDa band, which matched well with the predicted relative molecular mass of 43 kDa for the rat prostanoid EP1 receptor [7].

Discussion

The main objective of the present study was to identify the prostanoid receptors involved in regulation of the spontaneous beating rate of neonatal rat cardiomyocytes. We chose to use mainly specific agonists for this purpose, given that (i) very few antagonists with a demonstrated specificity for rat prostanoid receptors are available and (ii) the pattern of responses with the various agonists was sufficient to provide evidence of the receptors' respective involvements.

Effects of prostanoid FP and IP receptor agonists

A decrease in the beating rate was observed in presence of prostanoid FP and IP receptor agonists. Swiss 3T3 mouse fibroblast and A7r5 rat aorta smooth muscle cell lines [16,17] are known to express only the prostanoid FP receptor; PGF2α, fluprostenol, cloprostenol and latanoprost are potent agonists in these cell lines, whereas iloprost (a prostanoid IP receptor agonist) is inactive. PGF2α has been reported to increase the beating rate of rat cardiomyocytes and to produce tachyarrhythmias [13]. In

![Graph showing the effect of sulprostone on the cardiomyocyte beating rate.](image-url)
addition to differences in the culture medium used to isolate and culture the cardiomyocytes (F-10 Nutrient Mixture (Ham) vs MEM), pre-treatment with indomethacin to avoid interference by the endogenous prostanooids may explain the contrasting effect observed with PGF2α in our cardiomyocyte preparation. In line with our result with PGF2α, fluroprostcolol, clonoprostenol and latanoprost induced a decrease in the neonatal rat cardiomyocytes’ beating rate, with potencies similar to those reported in 3T3 and AVt5 cell lines. These data strongly suggest that prostanooid FP receptors negatively regulate the spontaneous beating rate of rat cardiomyocytes. This finding is in agreement with (i) the expression of prostanooid FP receptors in rat heart, (ii) the large quantity of prostanooid FP receptor mRNA in neonatal rat cardiomyocytes and (iii) the negative regulatory function attributed to this receptor [18-20]. PGL2 has previously been shown to induce a marked reduction in the contraction rate of rat cardiomyocytes at concentrations over 1 μM [13]. However, the compound is chemically unstable and also acts as an agonist of prostanoid EP receptor subtypes [2]. It is therefore important to use selective, stable prostanoid IP receptor agonists to check that this type of receptor is indeed involved in negative regulation of the beating rate. Although, iloprost is more selective than PGL1 in most respects, the former compound exerts prostanooid EP1 and EP3 receptor agonist activity [7,8]. Beraprost is much more selective for prostanoid IP receptor as reported for cicaprost [8,21]. Since iloprost and beraprost induced a marked reduction in the beating rate (with potencies similar to the potencies or binding affinities described in other preparations [8]), these results provide evidence of the involvement of prostanoid IP receptors. Prostanoid IP receptors have been detected by Western immunoblotting in isolated adult rat cardiomyocyte [22]. These results taken as a whole suggest that prostanoid IP and FP receptors negatively regulate the spontaneous beating rate in neonatal rat cardiomyocytes.

Effects of prostanooid EP receptor agonists

An increase in the beating rate was observed on addition of prostanooid DP and EP receptor agonists. PGD2 acts mainly through stimulation of prostanooid DP receptors. However, PGD2 binds to the cloned murine prostanooid FP receptor expressed in CHO cells [8] and also acts as a partial agonist in cell lines expressing either mouse or rat endogenous prostanooid FP receptors [16,17]. Whatever the bindings of PGD2 on prostanooid FP receptors, the compound induced an increase in the cardiomyocyte beating rate. This finding suggests that prostanooid DP receptors positively regulate the spontaneous beating rate of rat cardiomyocytes. BW245C (a selective prostanooid DP receptor agonist that does not bind to the DP2 receptor and other prostanooid receptors [8,16,23-25]) also induced an increase in the beating rate; this observation provides further evidence that prostanooid DP1 receptors are involved in upregulation of the spontaneous beating rate in this cell type. Although the prostanooid DP1 and DP2 receptors are both expressed in rat heart [19,29], prostanooid DP2 receptors do not appear to modulate the heart rate [26,27]; this contrasts with our present finding for prostanooid DP1 receptors in rat cardiomyocytes and with the increase in the heart rate after administration to man of BW-245C [28,29].

U-46619 is a highly potent, selective agonist of prostanooid TP receptors [2]. This finding suggests that functional TP receptors positively regulate the spontaneous beating rate in this preparation. The expression of prostanooid TP receptors in rat ventricular tissue has been confirmed [19]. An isomer of PGE2α (8-iso PGE2α) has been shown to act on the TP receptor in various preparations but is much less potent than U-46619 [30,31]; this may explain why the isomer of PGE2α increased the cardiomyocyte beating rate to a less extent than U-46619 did.

Effects of prostanooid EP receptor agonists

We applied PGE2 and various selective, synthetic prostanooid agonists in an attempt to identify the functional EP receptor subtypes in rat cardiomyocytes. PGE2α is a non-selective agonist of EP receptor subtypes but also has agonistic activity for FP receptors [8]. As previously described for experiments with the same preparation [13], PGE2 did not significantly alter the cardiomyocyte beating rate. However, the compound’s lack of selectivity for prostanooid receptors may have masked positive or negative regulation of the beating rate in response to selective activation of EP receptor subtypes. At higher concentrations (2 to 10 μM), PGE2 reportedly produces tachyarrhythmia in neonatal rat cardiomyocytes [13]. Sulprostone is a potent, selective EP1 and EP3 receptor agonist but does not bind to other prostanooid EP receptor subtypes in the mouse and the rat [7,8]. In our hands, the compound induced a marked increase in the beating rate. Butaprost is a selective prostanooid EP2 receptor agonist in both the rat and the mouse [7,8]. Our finding that butaprost did not alter the spontaneous beating rate therefore rules out a regulating role for prostanooid EP2 receptors. Misoprostol is considered to be an agonist of prostanooid EP1 and EP3 receptor subtypes [2,32,33] but binds mainly to the EP1 receptor in the rat [7]. Misoprostol did not alter the beating rate of rat cardiomyocytes. Since the results with butaprost ruled out the involvement of prostanooid EP2 receptors, the data obtained with misoprostol further suggest that prostanooid EP3 receptors are also not involved in regulation of the beating rate of rat cardiomyocytes. 11-deoxy-PGE2 is an agonist of prostanooid EP2, EP3 and EP1 receptors [7,8]. It has a 10- to 30-fold higher affinity for EP3 receptors than for EP2 receptors [7,8]. We found that 11-deoxy-PGE2 was devoid of any significant effect on the beating rate of rat cardiomyocytes, which again suggests that prostanooid EP2 and EP3 receptors (as well as EP1 receptors) are not involved in this process. The involvement of prostanooid EP1 receptors (relative to the other subtypes) was confirmed by the observed, inhibitory effect of SC-19220 (a specific antagonist on rat prostanooid EP1 receptors [6,7]). We chose to use SC-19220 alone because other antagonists (such as AH6809, ONO-AE3-208 and ONO-8711) are non-selective EP antagonists in rat or only characterized in mouse preparations.

A previous study has reported that transcripts for all four prostanooid EP receptor subtypes were expressed by rat neonatal cardiomyocytes [34]. Three subtypes (EP1, EP3, EP4) have been detected by Western blotting in adult rat cardiomyocytes but the EP1 and EP3 receptors were the most abundant [22]. In the present study, the expression of prostanooid EP1 receptors on neonatal rat cardiomyocytes was confirmed at the protein level. These results provide persuasive evidence that rat heart predominantly expresses the prostanooid EP1 receptor subtype. Our results

**Figure 3. Western blot analysis of prostanooid EP1 receptor subtype in rat cardiomyocytes.** Cells were cultured with 10% foetal calf serum (FCS+) for 3 days (as a control experiment) or then additionally incubated for 1 hour with 2% FCS and 1 μM indomethacin (FCS-), as performed in the functional experiments. The apparent mobility of the receptor was 42 kDa.

doi:10.1371/journal.pone.0045273.g003
constitute the first demonstration that prostaglandin EP1 receptors can positively regulate the beating rate of cardiomyocytes. In other respects, prostaglandin EP1 and EP2 receptors are respectively involved in cardiomyocyte protection from oxidative stress [22], and PGE2-induced hypertrophic changes [34].

In conclusion, our results suggest that spontaneous beating rate of neonatal rat ventricular cardiomyocytes is negatively regulated by prostaglandin IP and FP receptors and positively regulated by prostaglandin TP, DP1, and EP1 receptors (Fig. 4). The synthesis of prostanooids in the heart is primarily determined by both the coronary vasculature (endothelium and vascular smooth muscle), and the cardiomyocytes [1,9,35]. It is difficult to estimate prostanooid concentrations in the myocardium from rates of release into the culture medium or coronary veins when variables such as prostanooid turnover are not known. In addition to PGE2 and PGF2α (which are synthesized by the heart), PGI2 appears to be the predominant prostanooid released by rat ventricular cardiomyocytes, isolated rat or rabbit hearts or present in the blood of the human coronary sinus [1,9,36]. The direct effects of locally produced prostanooids on the beating rate of rat ventricular cardiomyocytes result from the balance between negative regulation by prostaglandin IP and FP receptors and positive regulation by prostaglandin TP, DP1 and EP1 receptors. The cell signalling mechanisms by which prostanooids might alter the electrical excitability of rat cardiomyocytes (e.g. the modification of ion channels) have, to the best of our knowledge, never been studied and thus require specific investigation. Since regulation of the beating rate also involves neurogenic, circulating, humoral factors or eicosanoids other than prostanooids, it is therefore even more complicated to explain or predict the in vivo outcome on the basis of in vitro data. However, cardiac synthesis of prostanooids is enhanced by the induction of hypoxia in isolated heart preparations or after in situ ischemia produced by coronary ligation [1]. Furthermore, prostanooid synthesis is known to be involved in the mechanism whereby ischemic preconditioning protects against reperfusion-induced tachyarrhythmia [11]. Cyclooxygenase (COX)-2 (the inducible form of COX) reportedly mediates the cardioprotective effects of the late phase of ischemic preconditioning by increasing the synthesis of prostanooids such as PGI2 and PGE2 [22,37]. The cardioprotective effects of PGI2 have been ascribed to the opening of mitochondrial K(+)ATP channels [22]. It is interesting to note that chronic treatment of normotenive and spontaneously hypertensive rats with iloprost reduced the incidence of reperfusion-induced arrhythmia [38]. In addition, COX-2-derived PGI2 has been found to mediate not only ischemic preconditioning but also isoflurane- and diazoxide-induced preconditioning in vivo [39]. On the whole, the cardiac prostanooids’ effect is due (at least in part) to their regulatory actions on the cardiomyocyte beating rate.

Acknowledgments

The authors wish to thank Professor H. Millard who gave initial technical supervision to H. Mechiche concerning the rat cardiomyocyte cultures.

Author Contributions

Conceived and designed the experiments: HM PD. Performed the experiments: HM AR. Analyzed the data: PN SGD PD. Contributed reagents/materials/analysis tools: PD. Wrote the paper: SGD PD.

References

1. Karmazyn M, Dhallan NS (1983) Physiological and pathophysiological aspects of cardiac prostaglandins. Can J Physiol Pharmacol 61: 1207–1225.
2. Coleman RA, Smith WL, Narumiya S (1994) International Union of Pharmacology classification of prostanooid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205–229.
3. Kennedy I, Coleman RA, Humphrey PP, Levy GP, Lumley P (1982) Studies on the characterisation of prostanooid receptors: a proposed classification. Prostaglandins 24: 667–689.
4. Woodward DF, Jones RL, Narumiya S (2011) International Union of Basic and Clinical Pharmacology. LXXIII: classification of prostanooid receptors, updating 15 years of progress. Pharmacol Rev 63: 471–538.
5. Abramovitz M, Adam M, Boie Y, Carrier M, Denis D, et al. (2000) The utilization of recombinant prostanooid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochem Biophys Acta 1483: 285–293.
6. Jones RL, Giembycz MA, Woodward DF (2009) Prostaglandin receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 158: 104–145.
7. Boie Y, Stocco R, Sawyer N, Silpeta DM, Ungrin MD, et al. (1997) Molecular cloning and characterization of the four rat prostaglandin E2 prostanooid receptor subtypes. Eur J Pharmacol 340: 227–241.
8. Kuriyama M, Usukihi F, Kobayashi T, Hirata M, Sagimoto Y, et al. (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanooid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122: 217–224.
9. Oudot F, Grynbach A, Sercier JP (1995) Eicosanoid synthesis in cardiomyocytes: influence of hypoxia, roxoygenation, and polyunsaturated fatty acids. Am J Physiol 268: H308–315.
10. Takayama K, Yoshii K, Ono K, Fujino T, Hara A, et al. (2005) Thromboxane A2 and prostaglandin E2 mediate inflammatory tachycardia. Nat Med 11: 562–566.
11. Arad M, Otsman T, Leor R, Rabiniowitz B (1996) Prostaglandins and the antiaarrhythmic effect of preconditioning in the isolated rat heart. Mol Cell Biochem 160–161: 299–305.
12. Birciuglo M, Olmez E, Aksoy T, Aset A (1997) The role of prostaglandin synthesis stimulation in the protective effect of captopril on ischaemia-reperfusion arrhythmias in rats in vivo. Pharmacol Res 36: 299–304.
13. Li Y, Kang JX, Leaf A (1997) Differential effects of various eicosanoids on the production or prevention of arrhythmias in cultured neonatal rat cardiomyocytes. Prostaglandins 54: 511–530.
14. Athia P, Felain G, Groz B, Dumas JP, Klepping J, et al. (1979) Myocardial electrophysiology: intracellular studies on heart cell cultures from newborn rats. Pathol Biol (Paris) 27: 13–19.
15. Kunapuli P, Lawson JA, Rokach JA, Meinkoth JL, FitzGerald GA (1998) Prostaglandin Flapla (PGF2alpha) and the isoprostane, 8,12-isoprostane Flapla-H, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J Biol Chem 273: 22442–22452.
16. Griffin BW, Magino PE, Pang IH, Sharif NA (1998) Pharmacological characterization of an FP prostanooid receptor on rat vascular smooth muscle.
cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J Pharmacol Exp Ther 286: 411–418.
17. Griffin BW, Williams GW, Crider JY, Sharif NA (1997) FP prostaglandin receptors mediating mitotot phosphates generation and calcium mobilization in Swiss 3T3 cells: a pharmacological study. J Pharmacol Exp Ther 201: 845–854.
18. Adams JW, Mipta DS, Yu MK, Young R, Hellekson MS, et al. (1996) Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem 271: 1179–1186.
19. Jovanovic N, Pavlovic M, Mrcevski V, Du Q, Jovanovic A (2006) An unexpected negative inotropic effect of prostaglandin F2alpha in the rat heart. Prostaglandins Other Lipid Mediat 80: 110–119.
20. Ocklind A, Lake S, Krook K, Hallin I, Nister M, et al. (1997) Localization of the prostaglandin F2 alpha receptor in rat tissues. Prostaglandins Leukot Essent Fatty Acids 57: 527–532.
21. Morrison K, Ernst R, Hess P, Studer R, Clozel M (2010) Selecsipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther 333: 249–255.
22. Shinmura K, Tamaki K, Sato T, Ishida H, Bolli R (2005) Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor. Am J Physiol Cell Physiol 288: H2093–2101.
23. Shichijo M, Sugimoto H, Nagao K, Inbe H, Encinas JA, et al. (2003) Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leucocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats. J Pharmacol Exp Ther 307: 518–525.
24. Walch L, Labat C, Gascard JP, de Montpreville V, Brink C, et al. (1999) Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol 126: 859–866.
25. Woodward DF, Fairbairn CE, Krauss AH, Lawrence RA, Protzman CE (1995) Radioligand binding analysis of receptor subtypes in two FP receptor preparations that exhibit different functional rank orders of potency in response to prostaglandins. J Pharmacol Exp Ther 273: 285–287.
26. Ishizuka T, Matsui T, Kurita A (2003) Ramatroban, a TP receptor antagonist, improves vasoactive responses to acetylcholine in hypercholesterolemic rabbits in vivo. Eur J Pharmacol 468: 27–35.
27. Johnston SL, Bardin PG, Harrison J, Ritter W, Joubert JR, et al. (1992) The effects of an oral thromboxane TP receptor antagonist BAY u 5403, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations. Br J Clin Pharmacol 34: 402–408.
28. Al-Sinawi LA, Mekki QA, Hassan S, Hedges A, Burke C, et al. (1985) Effect of a hydroxyeicosatetraenoic analogue, BV245C, during oral dosing in man. Prostaglandins 29: 99–111.
29. Orchard MA, Ritter JM, Shepherd GL, Lewis PJ (1983) Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2). Br J Clin Pharmacol 15: 509–511.
30. Cracowski JL, Devillier P, Durand T, Stanke-Labesque F, Bessard G (2001) Vascular biology of the isoprostanes. J Vasc Res 38: 93–103.
31. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, et al. (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 87: 9393–9387.
32. Lydford SJ, McKechnie K (1994) Characterization of the prostaglandin E2 sensitive (EP)-receptor in the rat isolated trachea. Br J Pharmacol 112: 133–136.
33. Meja KK, Barnes PJ, Gribelyc MA (1997) Characterization of the prostaglandin receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol 122: 149–157.
34. Miyatake S, Manabe-Kawauchi H, Watanabe K, Hori S, Aikawa N, et al. (2007) Prostaglandin E2 induces hypertrophic changes and suppresses alpha-skeletal actin gene expression in rat cardiomyocytes. J Cardiovasc Pharmacol 50: 548–554.
35. Jenkins CM, Cedars A, Gross RW (2009) Eicosanoid signalling pathways in the heart. Cardiovasc Res 82: 240–249.
36. Mattern R, Stone GP, Balhur N, Kuryhev YA (2001) Increased release of arachidonic acid and eicosanoids in iron-overloaded cardiomyocytes. Circulation 103: 2395–2401.
37. Bolli R, Shinmura K, Tang HL, Kodani E, Xuan YT, et al. (2002) Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55: 506–519.
38. Tosaki A, Kolai M, Paubert-Braclet M (1990) Effect of iloprost on reperfusion-induced arrhythmias and myocardial ion shifts in isolated rat hearts. Eur J Pharmacol 191: 69–81.
39. Alcindor D, Krolkowski JG, Pagel PS, Wartiner DG, Kersten JR (2004) Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology 100: 547–554.